Skip to main content
Premium Trial:

Request an Annual Quote

John Puisis Takes Helm at Third Wave, Roger Attick Named CEO of CeMines, Yashuhiro Kuroda Heads GeneBio s Japan Branch, Michael Olex Joins BioTrove from US Genomics, GenoMed Names Execs, and Others

John Puisis has become CEO and a director of Third Wave Technologies, replacing Lance Fors, who has become executive chairman "in order to dedicate his efforts toward the assessment and development of next generation technologies," the company said last week. Fors has already been serving as Third Wave's president and COO.


 

Roger Attick has become president, CEO, and a director of CeMines, the Evergreen, Colo.-based company said last week. Former CEO Bailey Dotson has become vice chairman of the board of directors, and former president Richard Cavalli will remain chairman of the board. Attick has been a venture partner with Artiman Ventures since 2000. He studied electrical engineering at the University of Arizona.

 

CeMines has developed technology for early-stage diagnostics of cancer and related diseases.


 

Robyn Owens has become CFO of St. Louis, Mo.-based GenoMed, the company said yesterday. Andy O'Guin has joined the company as chief technical officer, coming from a private St. Louis biotechnology company. Further, Ellen Jones was hired as vice president for marketing.


 

Alan Edrick will become executive vice president and CFO of BioSource International on May 17, replacing Charles Best who resigned "to pursue other opportunities," the company said on Monday. Edrick joins the Camarillo, Calif.-based BioSource from North American Scientific, where he was senior vice president and CFO. He holds a BA from the University of California, Los Angeles and an MBA from the Anderson School at UCLA.


 

Yasuhiro Kuroda has become business manager of Geneva Bioinformatics and will head the Swiss company's new Tokyo branch, GeneBio said yesterday. He also represents two other Swiss bioinformatics organizations in Japan. Most recently, he held various positions with Japanese companies Infocom and Teijin Systems Technology. Kuroda received a PhD in pharmaceutical science and a BS in plant genetics from Yokohama City University.


 

Michael Olex has become vice president of manufacturing for BioTrove, the Woburn, Mass.-based company said last week. He joins the company from US Genomics, where he was senior vice president for manufacturing and operations. Olex holds an MS in electrical engineering from Cleveland State University, an MBA from Case Western Reserve University, and a BS in electrical engineering from the University of Detroit.


 

Thomas Crompton has become vice president of sales and Thomas Chen vice president of marketing of Oscient Pharmaceuticals, the company said on Monday.

 

Crompton joins Oscient from Abbott Laboratories, where he held various sales-related positions. He received a BS in education from Clarion University of Pennsylvania.

 

Chen comes to Oscient from Cubist Pharmaceuticals, where he was executive director of marketing. He holds a BS in biology from Boston College.

 

Oscient, located in Waltham, Mass., results from the merger of Genome Therapeutics and Genesoft Pharmaceuticals.


 

Katherine Webster has joined Biotage-Biosystems as vice president of sales and marketing for North America, the company said last week.  Prior to joining the Westborough, Mass.-based company, she was director of sales development at Molecular Staging. Webster holds a BS in chemistry from SUNY College of Environmental Science and Forestry.


 

Rob Thomas has become a non-executive director and deputy chairman of the board of Benitec, the St. Lucia, Australia-based RNAi company said last week. He is the chairman of Citigroup Global Corporate & Investment Bank in Australia and New Zealand.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.